AbCellera Prices Oversubscribed $200M Offering at $9.75, Above Recent Lows
ABCL has more than doubled off its 52-week low of $2.745 on elevated volume (1.9× avg).
Summary
AbCellera priced its $200M public offering at $9.75 per share, a modest discount to the $10.32 market price but well above the 52-week low of $2.745. The deal was oversubscribed, with 17.4M common shares and 3.1M pre-funded warrants sold. This follows the August 11 announcement of the offering, which came one day after positive Phase 2 data for ABCL635 sent shares higher. The pricing confirms strong institutional demand for the stock at current levels. Proceeds will fund the ABCL635 clinical program and general corporate purposes, including continued research, development and clinical advancement of its internal pipeline. Closing is expected August 14, 2026.
At the time of this announcement, ABCL was trading at $10.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $2.75 to $10.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.